# Permeability Enhancement to Reduce Chronic Inflammation

> **NCT01582893** · NA · COMPLETED · sponsor: **Vantive Health LLC** · enrollment: 50 (actual)

## Conditions studied

- End Stage Renal Disease
- Inflammation

## Interventions

- **DEVICE:** HCO1100
- **DEVICE:** P210H

## Key facts

- **NCT ID:** NCT01582893
- **Lead sponsor:** Vantive Health LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2012-10
- **Final completion:** 2013-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2025-03-13

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01582893

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01582893, "Permeability Enhancement to Reduce Chronic Inflammation". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01582893. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*